Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes

Pharmacological Research

Volumn 103, Issue , 2016, Pages 26-48

  Roskoski, Robert ^a  

^a Blue Ridge Institute for Medical Research   (United States)

Author keywords

ATP binding site; Catalytic spine; K E D D; Protein kinase structure; Regulatory spine; Residence time

Indexed keywords

3 (2,3 DIHYDROXYPROPYL) 6 FLUORO 5 (2 FLUORO 4 IODOANILINO) 8 METHYLPYRIDO[2,3 D]PYRIMIDINE 4,7 DIONE; AFATINIB; AXITINIB; BOSUTINIB; CABOZANTINIB; CERITINIB; CRIZOTINIB; DASATINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IBRUTINIB; IMATINIB; LAPATINIB; LENVATINIB; NILOTINIB; NINTEDANIB; PALBOCICLIB; PONATINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RAPAMYCIN; RUXOLITINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOFACITINIB; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB;

AMINO ACID SEQUENCE; BINDING SITE; BREAST CANCER; CATALYSIS; CHEMICAL STRUCTURE; CHRONIC MYELOID LEUKEMIA; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG CLASSIFICATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME CONFORMATION; FIBROSING ALVEOLITIS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; KIDNEY CARCINOMA; MEAN RESIDENCE TIME; MELANOMA; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; THYROID CANCER; THYROID MEDULLARY CARCINOMA; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMISTRY; CLASSIFICATION; MOLECULARLY TARGETED THERAPY;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS;

EID: 84947744392     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.10.021     Document Type: Review

References (109)

1. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
2. A. Alonso, J. Sasin, N. Bottini, I. Friedberg, I. Friedberg, A. Osterman, and et al. Protein tyrosine phosphatases in the human genome Cell 117 2004 699 711
3. A. Bononi, C. Agnoletto, E. De Marchi, S. Marchi, S. Patergnani, M. Bonora, and et al. Protein kinases and phosphatases in the control of cell fate Enzyme Res. 2015 10.4061/2011/329098
4. P. Cohen Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1 2002 309 315
5. R. Roskoski Jr. STI-571: an anticancer protein-tyrosine kinase inhibitor Biochem. Biophys. Res. Commun. 309 2003 709 717
6. D.R. Knighton, J.H. Zheng, L.F. Ten Eyck, V.A. Ashford, N.H. Xuong, S.S. Taylor, and et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 1991 407 414
7. D.R. Knighton, J.H. Zheng, L.F. Ten Eyck, N.H. Xuong, S.S. Taylor, and J.M. Sowadski Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 1991 414 420
8. S.S. Taylor, M.M. Keshwani, J.M. Steichen, and A.P. Kornev Evolution of the eukaryotic protein kinases as dynamic molecular switches Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 2012 2517 2528
9. S.K. Hanks, A.M. Quinn, and T. Hunter The protein kinase family: conserved features and deduced phylogeny of the catalytic domains Science 241 1988 42 52
10. H.S. Meharena, P. Chang, M.M. Keshwani, K. Oruganty, A.K. Nene, N. Kannan, and et al. Deciphering the structural basis of eukaryotic protein kinase regulation PLoS Biol. 11 2013 e1001680
11. B. Nolen, S. Taylor, and G. Ghosh Regulation of protein kinases; controlling activity through activation segment conformation Mol. Cell 15 2004 661 675
12. N. Gotoh, A. Tojo, M. Hino, Y. Yazaki, and M. Shibuya A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor Biochem. Biophys. Res. Commun. 186 1992 768 774
13. D.A. Tice, J.S. Biscardi, A.L. Nickles, and S.J. Parsons Mechanism of biological synergy between cellular Src and epidermal growth factor receptor Proc. Natl. Acad. Sci. U. S. A. 96 1999 1415 1420
14. M. Huse, and J. Kuriyan The conformational plasticity of protein kinases Cell 109 2002 275 282
15. A.P. Kornev, N.M. Haste, S.S. Taylor, and L.F. Ten Eyck Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proc. Natl. Acad. Sci. U. S. A. 103 2006 17783 17788
16. A.P. Kornev, S.S. Taylor, and L.F. Ten Eyck A helix scaffold for the assembly of active protein kinases Proc. Natl. Acad. Sci. U. S. A. 105 2008 14377 14382
17. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
18. A.C. Dar, and K.M. Shokat The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling Annu. Rev. Biochem. 80 2011 769 795
19. J. Monod, J.P. Changeux, and F. Jacob Allosteric proteins and cellular control systems J. Mol. Biol. 6 1963 306 329
20. F. Zuccotto, E. Ardini, E. Casale, and M. Angiolini Through the gatekeeper door: exploiting the active kinase conformation J. Med. Chem. 53 2010 2681 2694
21. L.K. Gavrin, and E. Saiah Approaches to discover non-ATP site inhibitors Med. Chem. Commun. 4 2013 41
22. V. Lamba, and I. Ghosh New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors Curr. Pharm. Des. 18 2012 2936 2945
23. J.J. Liao Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors J. Med. Chem. 50 2007 409 424
24. O.P. van Linden, A.J. Kooistra, R. Leurs, I.J. de Esch, and C. de Graaf KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space J. Med. Chem. 57 2014 249 277
25. B. Nagar, W.G. Bornmann, P. Pellicena, T. Schindler, D.R. Veach, W.T. Miller, and et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 62 2002 4236 4243
26. D. Fabbro, S.W. Cowan-Jacob, and H. Moebitz Ten things you should know about protein kinases: IUPHAR review 14 Br. J. Pharmacol. 172 2015 2675 2700
27. P.Y. Yip Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer Transl. Lung Cancer Res. 4 2015 165 176
28. S. Romano, A. D'Angelillo, and M.F. Romano Pleiotropic roles in cancer biology for multifaceted proteins FKBPs Biochim. Biophys. Acta 1850 2015 2061 2068
29. H. Yang, D.G. Rudge, J.D. Koos, B. Vaidialingam, H.J. Yang, and N.P. Pavletich mTOR kinase structure, mechanism and regulation Nature 497 2013 217 223
30. R. Roskoski Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer Biochem. Biophys. Res. Commun. 319 2004 1 11
31. R. Roskoski Jr. The ErbB/HER family of protein-tyrosine kinases and cancer Pharmacol. Res. 79 2014 34 74
32. R. Roskoski Jr. ErbB/HER protein-tyrosine kinases: structures and small molecule inhibitors Pharmacol. Res. 87 2014 42 59
33. C.H. Yun, K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, K.K. Wong, and et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U. S. A. 105 2008 2070 2075
34. C.H. Yun, T.J. Boggon, Y. Li, M.S. Woo, H. Greulich, M. Meyerson, and et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11 2007 217 227
35. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. De Placido, and et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin. Cancer Res. 6 2000 2053 2063
36. P.M. Ellis, N. Coakley, R. Feld, S. Kuruvilla, and Y.C. Ung Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review Curr. Oncol. 22 2015 e183 e215
37. J. Stamos, M.X. Sliwkowski, and C. Eigenbrot Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 277 2002 46265 46272
38. A. Cid-Arregui, and V. Juarez Perspectives in the treatment of pancreatic adenocarcinoma World J. Gastroenterol. 21 2015 9297 9316
39. J.D. Rowley Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 1973 290 293
40. J. Groffen, J.R. Stephenson, N. Heisterkamp, A. de Kein, C.R. Bartram, and G. Grosveld Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 Cell 36 1984 93 99
41. E. Jabbour, H. Kantarjian, and J. Cortes Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm Clin. Lymphoma Myeloma Leuk. 15 2015 323 334
42. J.S. Tokarski, J.A. Newitt, C.Y. Chang, J.D. Cheng, M. Wittekind, S.E. Kiefer, and et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Res. 66 2006 5790 5797
43. T. O'Hare, D.K. Walters, E.P. Stoffregen, T. Jia, P.W. Manley, J. Mestan, and et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res. 65 2005 4500 4505
44. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401
45. M.S. Mathisen, H.M. Kantarjian, J. Cortes, and E.J. Jabbour Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia Blood Rev. 28 2014 179 187
46. M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
47. R. Roskoski Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition Pharmacol. Res. 68 2013 68 94
48. R. Roskoski Jr. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders Expert. Opin. Drug Discov. 8 2013 1165 1179
49. M. Soda, Y.L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, and et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
50. K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, and et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
51. J.J. Cui, M. Tran-Dubé, H. Shen, M. Nambu, P.P. Kung, M. Pairish, and et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 54 2011 6342 6363
52. M.A. Davare, N.A. Vellore, J.P. Wagner, C.A. Eide, J.R. Goodman, A. Drilon, and et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors Proc. Natl. Acad. Sci. U. S. A. 112 2015 E5381 E5390
53. R. Roskoski Jr. A historical overview of protein kinases and their targeted small molecule inhibitors Pharmacol. Res. 100 2015 1 23
54. B.C. Liao, C.C. Lin, J.Y. Shih, and J.C. Yang Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Ther. Adv. Med. Oncol. 7 2015 274 290
55. L. Friboulet, N. Li, R. Katayama, C.C. Lee, J.F. Gainor, A.S. Crystal, and et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer Cancer Discov. 4 2014 662 673
56. A. Quintás-Cardama, K. Vaddi, P. Liu, T. Manshouri, J. Li, P.A. Scherle, and et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms Blood 115 2010 3109 3117
57. B.L. Stein, S.T. Oh, D. Berenzon, G.S. Hobbs, M. Kremyanskaya, R.K. Rampal, C.N. Abboud, and et al. Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F J. Clin. Oncol. 2015 pii: JCO.2015.61.6474
58. Y. Duan, L. Chen, Y. Chen, and X.G. Fan c-Src binds to the cancer drug ruxolitinib with an active conformation PLoS One 9 2014 e106225
59. P.P. Knowles, J. Murray-Rust, S. Kjaer, R.P. Scott, S. Hanrahan, M. Santoro, and et al. Structure and chemical inhibition of the RET tyrosine kinase domain J. Biol. Chem. 281 2006 33577 33587
60. P. Fallahi, F. Di Bari, S.M. Ferrari, R. Spisni, G. Materazzi, P. Miccoli, and et al. Selective use of vandetanib in the treatment of thyroid cancer Drug Des. Dev. Ther. 9 2015 3459 3470
61. A. Morabito, M.C. Piccirillo, F. Falasconi, G. De Feo, A. Del Giudice, J. Bryce, and et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions Oncologist 14 2009 378 390
62. N.M. Levinson, and S.G. Boxer A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity Nat. Chem. Biol. 10 2014 127 132
63. J.E. Chrencik, A. Patny, I.K. Leung, B. Korniski, T.L. Emmons, T. Hall, and et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6 J. Mol. Biol. 400 2010 413 433
64. N.K. Williams, R.S. Bamert, O. Patel, C. Wang, P.M. Walden, A.F. Wilks, and et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains J. Mol. Biol. 387 2009 219 232
65. M. Malumbres Cyclin-dependent kinases Genome Biol. 15 2014 122
66. K.A. Cadoo, A. Gucalp, and T.A. Traina Palbociclib: an evidence-based review of its potential in the treatment of breast cancer Breast Cancer (Dove Med. Press) 6 2014 123 133
67. H. Lu, and U. Schulze-Gahmen Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition J. Med. Chem. 49 2006 3826 3831
68. R. Roskoski Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors Pharmacol. Res. 94 2015 9 25
69. J.C. Montero, S. Seoane, A. Ocaña, and A. Pandiella Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors Clin. Cancer Res. 17 2011 5546 5552
70. M.A. Eldeeb, and R.P. Fahlman The anti-apoptotic form of tyrosine kinase Lyn that is generated by proteolysis is degraded by the N-end rule pathway Oncotarget 5 2014 2714 2722
71. E.R. Wood, A.T. Truesdale, O.B. McDonald, D. Yuan, A. Hassell, S.H. Dickerson, and et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 64 2004 6652 6659
72. R. Roskoski Jr. ERK1/2 MAP kinases: structure, function, and regulation Pharmacol. Res. 66 2012 105 143
73. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, H. Cho, and et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma Nature 467 2010 596 599
74. G. Bollag, J. Tsai, J. Zhang, C. Zhang, P. Ibrahim, K. Nolop, and P. Hirth Vemurafenib: the first drug approved for BRAF -mutant cancer Nat. Rev. Drug Discov. 11 2012 873 886
75. R.D. Mazor, M. Manevich-Mazor, and Y. Shoenfeld Erdheim-Chester disease: a comprehensive review of the literature Orphanet J. Rare Dis. 8 2013 137
76. R. Roskoski Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression Crit. Rev. Oncol. Hematol. 62 2007 179 213
77. K. Okamoto, M. Ikemori-Kawada, A. Jestel, K. von König, Y. Funahashi, T. Matsushima, and et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization ACS Med. Chem. Lett. 6 2014 89 94
78. J.H. Park, Y. Liu, M.A. Lemmon, and R. Radhakrishnan Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain Biochem. J. 448 2012 417 423
79. M.P. Martin, R. Alam, S. Betzi, D.J. Ingles, J.Y. Zhu, and E. Schönbrunn A novel approach to the discovery of small-molecule ligands of CDK2 Chembiochem 13 2012 2128 2136
80. C. Birchmeier, W. Birchmeier, E. Gherardi, and G.F. Vande Woude Met, metastasis, motility and more Nat. Rev. Mol. Cell Biol. 4 2003 915 925
81. Z. Zhao, H. Wu, L. Wang, Y. Liu, S. Knapp, Q. Liu, and N.S. Gray Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 9 2014 1230 1241
82. R. Roskoski Jr. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor Biochem. Biophys. Res. Commun. 338 2005 1307 1315
83. R. Roskoski Jr. Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor Biochem. Biophys. Res. Commun. 337 2005 1 13
84. C.D. Mol, D.R. Dougan, T.R. Schneider, R.J. Skene, M.L. Kraus, D.N. Scheibe, and et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase J. Biol. Chem. 279 2004 31655 31663
85. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, and et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
86. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, and et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
87. E.V. Schneider, J. Böttcher, M. Blaesse, L. Neumann, R. Huber, and K. Maskos The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder J. Mol. Biol. 412 2011 251 266
88. M. McTigue, B.W. Murray, J.H. Chen, Y.L. Deng, J. Solowiej, and R.S. Kania Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors Proc. Natl. Acad. Sci. U. S. A. 109 2012 18281 18289
89. E. Weisberg, P.W. Manley, W. Breitenstein, J. Brüggen, S.W. Cowan-Jacob, A. Ray, and et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141
90. T. Zhou, L. Commodore, W.S. Huang, Y. Wang, M. Thomas, J. Keats, and et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance Chem. Biol. Drug Des. 77 2011 1 11
91. + cells Blood 92 1998 2461 2470
92. A.P. Garner, J.M. Gozgit, R. Anjum, S. Vodala, A. Schrock, T. Zhou, and et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients Clin. Cancer Res. 20 2014 5745 5755
93. K.S. Gajiwala, J.C. Wu, J. Christensen, G.D. Deshmukh, W. Diehl, J.P. DiNitto, and et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients Proc. Natl. Acad. Sci. U. S. A. 106 2009 1542 1547
94. M. Inomata, Y. Nishioka, and Azuma A. Nintedanib evidence for its therapeutic potential in idiopathic pulmonary fibrosis Core Evid. 10 2015 89 98
95. L. Farkas, D. Farkas, K. Ask, A. Möller, J. Gauldie, P. Margetts, and et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats J. Clin. Invest. 119 2009 1298 1311
96. F. Hilberg, G.J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, U. Tontsch-Grunt, and et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res. 68 2008 4774 4782
97. G.J. Roth, R. Binder, F. Colbatzky, C. Dallinger, R. Schlenker-Herceg, F. Hilberg, and et al. Nintedanib: from discovery to the clinic J. Med. Chem. 58 2015 1053 1063
98. F.J. Adrián, Q. Ding, T. Sim, A. Velentza, C. Sloan, Y. Liu, and et al. Allosteric inhibitors of Bcr-Abl-dependent cell proliferation Nat. Chem. Biol. 2 2006 95 102
99. Q. Dong, D.R. Dougan, X. Gong, P. Halkowycz, B. Jin, T. Kanouni, and et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer Bioorg. Med. Chem. Lett. 21 2011 1315 1319
100. P.A. Schwartz, and B.W. Murray Protein kinase biochemistry and drug discovery Bioorg. Chem. 39 2011 192 210
101. F. Solca, G. Dahl, A. Zoephel, G. Bader, M. Sanderson, C. Klein, and et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker J. Pharmacol. Exp. Ther. 343 2012 342 350
102. R.A. Copeland, D.L. Pompliano, and T.D. Meek Drug-target residence time and its implications for lead optimization Nat. Rev. Drug. Discov. 5 2006 730 739
103. P.J. Tummino, and R.A. Copeland Residence time of receptor-ligand complexes and its effect on biological function Biochemistry 47 2008 5481 5492 Erratum in: Biochemistry 2008; 47: 8465
104. R.A. Copeland Conformational adaptation in drug-target interactions and residence time Future Med. Chem. 3 2011 1491 1501
105. L. Neumann, K. von König, and D. Ullmann HTS reporter displacement assay for fragment screening and fragment evolution toward leads with optimized binding kinetics, binding selectivity, and thermodynamic signature Methods Enzymol. 493 2011 299 320
106. H. Möbitz The ABC of protein kinase conformations Biochim. Biophys. Acta 2015 1854 1555 1566
107. K. Parang, J.H. Till, A.J. Ablooglu, R.A. Kohanski, S.R. Hubbard, and P.A. Cole Mechanism-based design of a protein kinase inhibitor Nat. Struct. Biol. 8 2001 37 41
108. P. Cohen, and D.R. Alessi Kinase drug discovery - what's next in the field? ACS Chem. Biol. 8 2013 96 104
109. A. Levitzki Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance Annu. Rev. Pharmacol. Toxicol. 53 2013 161 185